Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 19.96 0.35% 0.07
SPPI closed up 0.35 percent on Tuesday, June 19, 2018, on approximately normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical SPPI trend table...

Date Alert Name Type % Chg
Jun 19 Bollinger Band Squeeze Range Contraction 0.00%
Jun 18 Hammer Candlestick Bullish 0.35%
Jun 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.35%
Jun 18 Bollinger Band Squeeze Range Contraction 0.35%
Jun 18 Doji - Bullish? Reversal 0.35%
Jun 15 MACD Bearish Signal Line Cross Bearish 0.05%
Jun 15 180 Bullish Setup Bullish Swing Setup 0.05%
Jun 15 Bollinger Band Squeeze Range Contraction 0.05%
Jun 15 Doji - Bullish? Reversal 0.05%
Jun 15 Multiple of Ten Bearish Other 0.05%

Older signals for SPPI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 23.5
52 Week Low 7.12
Average Volume 1,789,464
200-Day Moving Average 17.9057
50-Day Moving Average 18.6484
20-Day Moving Average 19.5825
10-Day Moving Average 20.047
Average True Range 0.8319
ADX 24.14
+DI 25.39
-DI 18.44
Chandelier Exit (Long, 3 ATRs ) 18.2043
Chandelier Exit (Short, 3 ATRs ) 20.1457
Upper Bollinger Band 20.7161
Lower Bollinger Band 18.4489
Percent B (%b) 0.67
BandWidth 11.577684
MACD Line 0.4669
MACD Signal Line 0.5065
MACD Histogram -0.0396
Fundamentals Value
Market Cap 1.57 Billion
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -19.96
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.97
Resistance 3 (R3) 20.87 20.43 20.80
Resistance 2 (R2) 20.43 20.18 20.48 20.74
Resistance 1 (R1) 20.20 20.02 20.32 20.30 20.69
Pivot Point 19.76 19.76 19.82 19.81 19.76
Support 1 (S1) 19.53 19.51 19.65 19.63 19.23
Support 2 (S2) 19.09 19.35 19.14 19.18
Support 3 (S3) 18.86 19.09 19.12
Support 4 (S4) 18.96